Login Register Cart 0
Generic placeholder image

Current Rheumatology Reviews

Editor-in-Chief

ISSN (Print): 1573-3971
ISSN (Online): 1875-6360

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Effects of Glucosamine in the Temporomandibular Joint Osteoarthritis: A Review

Author(s): Sasidharan Sivakumar, Gowardhan Sivakumar and Ashok K. Sundramoorthy*

Volume 20, Issue 4, 2024

Published on: 11 January, 2024

Page: [373 - 378] Pages: 6

DOI: 10.2174/0115733971283009231225144322

Price: $65

Abstract

Osteoarthritis in the temporomandibular joint (TMJ) is a chronic disease characterized by irreversible damage to articular surfaces, including inflammation, loss of articular cartilage, and subchondral bone alterations, which would be radiographically evident only in later stages. Symptomatic slow-acting so-called nutraceutical drugs have been proposed as a treatment for osteoarthritis in comparison to non-steroidal anti-inflammatory drugs (NSAID) because of their appreciable safety profile even in long-term intake. Glucosamine, being one among them, proved highly efficient in knee osteoarthritis. However, its application in TMJ osteoarthritis dates back only to 2001 and is still inconclusive in its efficiency even with systematic reviews, in restoring the structural and functional aspects of damaged TMJ. Glucosamine, being a natural compound and also a contributor to building the matrix of articular cartilage, can be utilized effectively for TMJ osteoarthritis as an adjunct along with other conventional treatment modalities available till now, which also have moderate prognosis in most of the clinical scenarios. This review summarizes data relating to the mechanism of osteoarthritis and its management using glucosamine formulations. The beneficial effects of glucosamine on the pathophysiology of TMJ osteoarthritis are possibly due to its contribution to hyaluronic acid regulation and in establishing a proper balance between anabolism/catabolism in the articular tissues.

« Previous Next »
Graphical Abstract

[1]
Stegenga B, de Bont LGM, Boering G. Osteoarthrosis as the cause of craniomandibular pain and dysfunction: A unifying concept. J Oral Maxillofac Surg 1989; 47(3): 249-56.
[http://dx.doi.org/10.1016/0278-2391(89)90227-9] [PMID: 2646405]
[2]
Stegenga B, De Bont LGM, Boering G, Van Willigen JD. Tissue responses to degenerative changes in the temporomandibular joint: A review. J Oral Maxillofac Surg 1991; 49(10): 1079-88.
[http://dx.doi.org/10.1016/0278-2391(91)90143-A] [PMID: 1890521]
[3]
Gibbs CH, Mahan PE, Mauderli A, Lundeen HC, Walsh EK. Limits of human bite strength. J Prosthet Dent 1986; 56(2): 226-9.
[http://dx.doi.org/10.1016/0022-3913(86)90480-4] [PMID: 3463748]
[4]
Helmy E, Bays R, Sharawy M. Osteoarthrosis of the temporomandibular joint following experimental disc perforation in Macaca fascicularis. J Oral Maxillofac Surg 1988; 46(11): 979-90.
[http://dx.doi.org/10.1016/0278-2391(88)90335-7] [PMID: 3183809]
[5]
Mills DK, Daniel JC, Herzog S, Scapino RP. An animal model for studying mechanisms in human temporomandibular joint disc derangement. J Oral Maxillofac Surg 1994; 52(12): 1279-92.
[http://dx.doi.org/10.1016/0278-2391(94)90051-5] [PMID: 7965332]
[6]
Dimitroulis G. The prevalence of osteoarthrosis in cases of advanced internal derangement of the Temporomandibular Joint: A clinical, surgical and histological study. Int J Oral Maxillofac Surg 2005; 34(4): 345-9.
[http://dx.doi.org/10.1016/j.ijom.2004.10.013] [PMID: 16053840]
[7]
de Bont LGM, Boering G, Liem RSB, Eulderink F, Westesson PL. Osteoarthritis and internal derangemen of the temporomandibular joint: A light microscopic study. J Oral Maxillofac Surg 1986; 44(8): 634-43.
[http://dx.doi.org/10.1016/S0278-2391(86)80075-1] [PMID: 3461142]
[8]
Blaustein DI, Scapino RP. Remodeling of the temporomandibular joint disk and posterior attachment in disk displacement specimens in relation to glycosaminoglycan content. Plast Reconstr Surg 1986; 78(6): 756-64.
[http://dx.doi.org/10.1097/00006534-198678060-00008] [PMID: 3786529]
[9]
McCord JM. Free radicals and inflammation: Protection of synovial fluid by superoxide dismutase. Science 1974; 185(4150): 529-31.
[http://dx.doi.org/10.1126/science.185.4150.529] [PMID: 4841157]
[10]
Sundblad L. Glycosaminoglycans and glycoproteins in synovial fluid. In: Balazs EA, Jeanloz RW, Eds. The Chemistry and Biology of Compounds Containing Amino Sugars I: The amino sugars. New York: Academic Press 1965; pp. 229-50.
[11]
Kobayashi Y, Okamoto A, Nishinari K. Viscoelasticity of hyaluronic acid with different molecular weights. Biorheology 1994; 31(3): 235-44.
[http://dx.doi.org/10.3233/BIR-1994-31302] [PMID: 8729484]
[12]
Mabuchi K, Obara T, Ikegami K, Yamaguchi T, Kanayama T. Molecular weight independence of the effect of additive hyaluronic acid on the lubricating characteristics in synovial joints with experimental deterioration. Clin Biomech 1999; 14(5): 352-6.
[http://dx.doi.org/10.1016/S0268-0033(98)00084-9] [PMID: 10521613]
[13]
Uitterlinden EJ, Koevoet JLM, Verkoelen CF, et al. Glucosamine increases hyaluronic acid production in human osteoarthritic synovium explants. BMC Musculoskelet Disord 2008; 9(1): 120.
[http://dx.doi.org/10.1186/1471-2474-9-120] [PMID: 18786270]
[14]
Smalley WE, Ray WA, Daugherty JR, Griffin MR. Nonsteroidal anti-inflammatory drugs and the incidence of hospitalizations for peptic ulcer disease in elderly persons. Am J Epidemiol 1995; 141(6): 539-45.
[http://dx.doi.org/10.1093/oxfordjournals.aje.a117469] [PMID: 7900721]
[15]
Dahmer S, Schiller RM. Glucosamine. Am Fam Physician 2008; 78(4): 471-6.
[PMID: 18756654]
[16]
Vynios DH. Metabolism of cartilage proteoglycans in health and disease. BioMed Res Int 2014; 2014: 1-9.
[http://dx.doi.org/10.1155/2014/452315] [PMID: 25105124]
[17]
Bruyère O, Honvo G, Veronese N, et al. An updated algorithm recommendation for the management of knee osteoarthritis from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Semin Arthritis Rheum 2019; 49(3): 337-50.
[http://dx.doi.org/10.1016/j.semarthrit.2019.04.008]
[18]
Owens S, Wagner P, Vangsness C Jr. Recent advances in glucosamine and chondroitin supplementation. J Knee Surg 2004; 17(4): 185-93.
[http://dx.doi.org/10.1055/s-0030-1248220] [PMID: 15553585]
[19]
Bassleer C, Henrotin Y, Franchimont P. In-vitro evaluation of drugs proposed as chondroprotective agents. Int J Tissue React 1992; 14(5): 231-41.
[PMID: 1300309]
[20]
Hungerford MW, Valaik D. Chondroprotective agents: Glucosamine and chondroitin. Foot Ankle Clin 2003; 8(2): 201-19.
[http://dx.doi.org/10.1016/S1083-7515(03)00043-3] [PMID: 12911236]
[21]
Tiku ML, Narla H, Jain M, Yalamanchili P. Glucosamine prevents in vitro collagen degradation in chondrocytes by inhibiting advanced lipoxidation reactions and protein oxidation. Arthritis Res Ther 2007; 9(4): R76.
[http://dx.doi.org/10.1186/ar2274] [PMID: 17686167]
[22]
Martel-Pelletier J, Boileau C, Pelletier JP, Roughley PJ. Cartilage in normal and osteoarthritis conditions. Best Pract Res Clin Rheumatol 2008; 22(2): 351-84.
[http://dx.doi.org/10.1016/j.berh.2008.02.001] [PMID: 18455690]
[23]
Dodge GR, Jimenez SA. Glucosamine sulfate modulates the levels of aggrecan and matrix metalloproteinase-3 synthesized by cultured human osteoarthritis articular chondrocytes. Osteoarthritis Cartilage 2003; 11(6): 424-32.
[http://dx.doi.org/10.1016/S1063-4584(03)00052-9] [PMID: 12801482]
[24]
Derfoul A, Miyoshi AD, Freeman DE, Tuan RS. Glucosamine promotes chondrogenic phenotype in both chondrocytes and mesenchymal stem cells and inhibits MMP-13 expression and matrix degradation. Osteoarthritis Cartilage 2007; 15(6): 646-55.
[http://dx.doi.org/10.1016/j.joca.2007.01.014] [PMID: 17337215]
[25]
Sandy JD, Gamett D, Thompson V, Verscharen C. Chondrocyte-mediated catabolism of aggrecan: aggrecanase-dependent cleavage induced by interleukin-1 or retinoic acid can be inhibited by glucosamine. Biochem J 1998; 335(1): 59-66.
[http://dx.doi.org/10.1042/bj3350059] [PMID: 9742213]
[26]
Block JA, Oegema TR, Sandy JD, Plaas A. The effects of oral glucosamine on joint health: Is a change in research approach needed? Osteoarthritis Cartilage 2010; 18(1): 5-11.
[http://dx.doi.org/10.1016/j.joca.2009.07.005] [PMID: 19733270]
[27]
Anderson JW, Nicolosi RJ, Borzelleca JF. Glucosamine effects in humans: A review of effects on glucose metabolism, side effects, safety considerations and efficacy. Food Chem Toxicol 2005; 43(2): 187-201.
[http://dx.doi.org/10.1016/j.fct.2004.11.006] [PMID: 15621331]
[28]
Persiani S, Roda E, Rovati LC, Locatelli M, Giacovelli G, Roda A. Glucosamine oral bioavailability and plasma pharmacokinetics after increasing doses of crystalline glucosamine sulfate in man. Osteoarthritis Cartilage 2005; 13(12): 1041-9.
[http://dx.doi.org/10.1016/j.joca.2005.07.009] [PMID: 16168682]
[29]
Persiani S, Rotini R, Trisolino G, et al. Synovial and plasma glucosamine concentrations in osteoarthritic patients following oral crystalline glucosamine sulphate at therapeutic dose. Osteoarthritis Cartilage 2007; 15(7): 764-72.
[http://dx.doi.org/10.1016/j.joca.2007.01.019] [PMID: 17353133]
[30]
Jackson CG, Plaas AH, Sandy JD, et al. The human pharmacokinetics of oral ingestion of glucosamine and chondroitin sulfate taken separately or in combination. Osteoarthritis Cartilage 2010; 18(3): 297-302.
[http://dx.doi.org/10.1016/j.joca.2009.10.013] [PMID: 19912983]
[31]
Setnikar I, Rovati L. Absorption, distribution, metabolism and excretion of glucosamine sulfate. A review. Arzneimittelforschung 2011; 51(9): 699-725.
[http://dx.doi.org/10.1055/s-0031-1300105] [PMID: 11642003]
[32]
Salazar J, Bello L, Chávez M, Añez R, Rojas J, Bermúdez V. Glucosamine for osteoarthritis: Biological effects, clinical efficacy, and safety on glucose metabolism. Arthritis 2014; 2014: 1-13.
[http://dx.doi.org/10.1155/2014/432463] [PMID: 24678419]
[33]
Bohne W. Glukosamine in der konservativen arthrosebehandlung. Med Welt 1969; 30: 1668-71.
[PMID: 5355658]
[34]
Pujalte JM, Llavore EP, Ylescupidez FR. Double-blind clinical evaluation of oral glucosamine sulphate in the basic treatment of osteoarthrosis. Curr Med Res Opin 1980; 7(2): 110-4.
[http://dx.doi.org/10.1185/03007998009112036] [PMID: 7002479]
[35]
D’Ambrosio E, Casa B, Bompani R, Scali G, Scali M. Glucosamine sulphate: A controlled clinical investigation in arthrosis. Pharmatherapeutica 1981; 2(8): 504-8.
[PMID: 7019929]
[36]
Noack W, Fischer M, Förster K, Rovati L, Setnikar I. Glucosamine sulfate in osteoarthritis of the knee. Osteoarthritis Cartilage 1994; 2(1): 51-9.
[http://dx.doi.org/10.1016/S1063-4584(05)80006-8] [PMID: 11548224]
[37]
Crolle G, D’este E. Glucosamine sulphate for the management of arthrosis: A controlled clinical investigation. Curr Med Res Opin 1980; 7(2): 104-9.
[http://dx.doi.org/10.1185/03007998009112035] [PMID: 7002478]
[38]
Setnikar I, Pacini MA, Revel L. Antiarthritic effects of glucosamine sulfate studied in animal models. Arzneimittelforschung 1991; 41(5): 542-5.
[PMID: 1898426]
[39]
Moriga M, Aono M, Murakami M, Uchino H. The activity of N-acetylglucosamine kinase in rat gastric mucosa. Gastroenterol Jpn 1980; 15(1): 7-13.
[http://dx.doi.org/10.1007/BF02773698] [PMID: 6244208]
[40]
Reichelt A, Forster KK, Fischer M, Rovati LC, Setnikar I. Efficacy and safety of intramuscular glucosamine sulphate in osteoarthritis of the knee. Arzneimittelforschung 1994; 44: 75-80.
[PMID: 8135881]
[41]
Tapadinhas MJ, Rivera IC, Bignamini AA. Oral glucosamine sulphate in the management of arthrosis: Report on a multi-centre open investigation in Portugal. Pharmatherapeutica 1982; 3(3): 157-68.
[PMID: 7134225]
[42]
Thie NM, Prasad NG, Major PW. Evaluation of glucosamine sulfate compared to ibuprofen for the treatment of temporomandibular joint osteoarthritis: A randomized double blind controlled 3 month clinical trial. J Rheumatol 2001; 28(6): 1347-55.
[PMID: 11409130]
[43]
Behnia A, Haghighat A, Kaviani N, Khorami B. Evaluation of Glucosamine sulfate and Ibuprofen effects in patients with temporomandibular joint osteoarthritis symptom. J Res Pharm Pract 2013; 2(1): 34-9.
[http://dx.doi.org/10.4103/2279-042X.114087] [PMID: 24991602]
[44]
Nguyen P, Mohamed SE, Gardiner D, Salinas T. A randomized double-blind clinical trial of the effect of chondroitin sulfate and glucosamine hydrochloride on temporomandibular joint disorders: A pilot study. Cranio 2001; 19(2): 130-9.
[http://dx.doi.org/10.1080/08869634.2001.11746162] [PMID: 11842864]
[45]
Damlar İ, Esen E, Tatli U. Effects of glucosamine-chondroitin combination on synovial fluid IL-1β, IL-6, TNF-α and PGE2 levels in internal derangements of temporomandibular joint. Med Oral Patol Oral Cir Bucal 2015; 20(3): e278-83.
[http://dx.doi.org/10.4317/medoral.20242] [PMID: 25662545]
[46]
Cahlin BJ, Dahlström L. No effect of glucosamine sulfate on osteoarthritis in the temporomandibular joints—a randomized, controlled, short-term study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2011; 112(6): 760-6.
[http://dx.doi.org/10.1016/j.tripleo.2011.06.012] [PMID: 22001199]
[47]
Cen X, Liu Y, Wang S, Yang X, Shi Z, Liang X. Glucosamine oral administration as an adjunct to hyaluronic acid injection in treating temporomandibular joint osteoarthritis. Oral Dis 2018; 24(3): 404-11.
[http://dx.doi.org/10.1111/odi.12760] [PMID: 28862770]
[48]
Yang W, Liu W, Miao C, Sun H, Li L, Li C. Oral glucosamine hydrochloride combined with hyaluronate sodium intra-articular injection for temporomandibular joint osteoarthritis: A double-blind randomized controlled trial. J Oral Maxillofac Surg 2018; 76(10): 2066-73.
[http://dx.doi.org/10.1016/j.joms.2018.04.031] [PMID: 29864430]
[49]
Cömert Kılıç S. Does glucosamine, chondroitin sulfate, and methylsulfonylmethane supplementation improve the outcome of temporomandibular joint osteoarthritis management with arthrocentesis plus intraarticular hyaluronic acid injection. A randomized clinical trial. J Craniomaxillofac Surg 2021; 49(8): 711-8.
[http://dx.doi.org/10.1016/j.jcms.2021.02.012] [PMID: 33685850]
[50]
Derwich M, Górski B, Amm E, Pawłowska E. Oral glucosamine in the treatment of temporomandibular joint osteoarthritis: A systematic review. Int J Mol Sci 2023; 24(5): 4925.
[http://dx.doi.org/10.3390/ijms24054925] [PMID: 36902359]
[51]
Williams C, Ampat G. Glucosamine Sulfate. StatPearls 2023.
[52]
Gray HC, Hutcheson PS, Slavin RG. Is glucosamine safe in patients with seafood allergy? J Allergy Clin Immunol 2004; 114(2): 459-60.
[http://dx.doi.org/10.1016/j.jaci.2004.05.050] [PMID: 15341031]
[53]
Knudsen JF, Sokol GH. Potential glucosamine-warfarin interaction resulting in increased international normalized ratio: Case report and review of the literature and MedWatch database. Pharmacotherapy 2008; 28(4): 540-8.
[http://dx.doi.org/10.1592/phco.28.4.540] [PMID: 18363538]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy